What You Should Know
- San Diego-based bioinformatics company Inocras Inc. closed an oversubscribed $31M Series B-3 financing round, bringing its total capital raised to approximately $100M.
- The funding round was supported by strategic investors NDS Corporation and Aimed Bio Inc., alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, and Shinhan Securities.
- Proceeds will fund the U.S. expansion of Inocras’s CLIA/CAP-certified whole-genome sequencing (WGS) and automated analytics infrastructure, transferring clinical models established across Asia.
- Inocras’s proprietary suite includes CancerVision™ for comprehensive somatic and germline tumor profiling and MRDVision™ for ultra-sensitive, whole-genome molecular residual disease tracking.
- The financing builds on real-world adoption across 100+ Asian cancer institutions and recent whole-genome research collaborations analyzing The Cancer Genome Atlas (TCGA) alongside the Broad Institute.
Automated Curation and Whole-Genome Analytics
The clinical oncology, precision diagnostics, and genomic bioinformatics sectors face a persistent operational challenge: the analytical ceiling of narrow gene panels. While targeted next-generation sequencing (NGS) panels capture common coding mutations, they frequently miss complex structural variants, non-coding driver alterations, and broader mutational signatures across the cancer genome.
As precision oncology moves toward comprehensive whole-genome interpretation, health systems require automated bioinformatics pipelines that translate billions of genomic data points into clinically actionable decisions without delaying patient treatment.
Leveraging extensive clinical adoption across Asia, the company is deploying the capital to build out its U.S. operational, commercial, and laboratory infrastructure. Inocras’s platform integrates automated interpretation algorithms with high-depth sequencing pipelines to streamline clinical decision support:
- CancerVision™ Comprehensive Profiling: Analyzes paired somatic and germline whole-genome data to identify single-nucleotide variants (SNVs), indels, copy-number alterations (CNAs), complex structural variants (SVs), and non-coding alterations, alongside biomarkers such as tumor mutational burden (TMB) and homologous recombination deficiency (HRD).
- MRDVision™ ctDNA Detection: Utilizes a whole-genome, panel-free circulating tumor DNA (ctDNA) tracking model to achieve ultra-sensitive molecular residual disease detection with limits of detection reaching down to 1 ppm.
- Demonstrated Regional Footprint: Capitalizes on existing clinical usage across 100+ Asian cancer centers, supporting approximately 30 hospitals in South Korea and establishing a major commercial hub in Hong Kong.
- Large-Scale Population Validation: Complements a recent collaboration with Broad Institute researchers analyzing thousands of TCGA cancer cases to establish standardized whole-genome curation benchmarks.
“We have already seen meaningful adoption across cancer institutions in Asia, where our technology has been used in thousands of patient cases,” stated Jehee Suh, Chief Executive Officer of Inocras.
As Inocras expands its CLIA/CAP-certified footprint into U.S. hospital networks, its whole-genome platform establishes a clear operational benchmark for how high-depth data automation will drive the future of precision oncology.
